percent of americans on glp 1 The GLP-1 Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs 12% of Americans have used

18 DuvoixA.SchmitzM.SchnekenburgerM.DicatoM.MorceauF.GalteauM

X.AugustinM

Proper disposal prevents injury and the spread of infection

The standard approach involves slowing dose escalation if side effects are severe, temporarily reducing the dose if a new tier causes significant discomfort, and providing dietary recommendations to minimize gastrointestinal symptoms

Three 20-week double-blind, placebo-controlled studies each with 34-week extensions were conducted to evaluate the efficacy and safety of sitagliptin in 410 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes, with or without insulin therapy (HbA1c 6.5-10% for patients not on insulin, HbA1c 7-10% for patients on insulin)

After a big year for GLP-1s, the biopharma market is shifting